Drug Profile
Research programme: parasitic infections therapeutics - Celgene Corporation/Drugs for Neglected Diseases Initiative Foundation
Alternative Names: CGH VL series; Neglected tropical disease therapeuticsLatest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation; Drugs for Neglected Diseases Initiative Foundation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Chagas disease; Elephantiasis; Leishmaniasis; Onchocerciasis
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 28 Oct 2018 No recent reports of development identified for research development in African trypanosomiasis in Switzerland
- 28 Oct 2018 No recent reports of development identified for research development in African trypanosomiasis in USA